SEC Form 10-K filed by LB Pharmaceuticals Inc
$LBRX
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/9/2026 | Buy | Roth Capital | |
| 10/6/2025 | $27.00 | Buy | Stifel |
| 10/6/2025 | $78.00 | Overweight | Piper Sandler |
| 10/6/2025 | $34.00 | Outperform | Leerink Partners |
Roth Capital initiated coverage of LB Pharmaceuticals with a rating of Buy
Stifel initiated coverage of LB Pharmaceuticals with a rating of Buy and set a new price target of $27.00
Piper Sandler initiated coverage of LB Pharmaceuticals with a rating of Overweight and set a new price target of $78.00
NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder (MDD), and other neuropsychiatric diseases, today announced the presentation of new data further evaluating the effects of LB-102 on cognitive performance in the Phase 2 NOVA-1 clinical trial in patients with acute schizophrenia. LB-102, a novel, once-daily, oral investigational small molecule, is a selective antagonist of D2, D3, and 5HT7 receptors that is being advanced as a potential first benzamide antipsychotic
Reported positive results from potentially registrational Phase 2 trial ofLB-102 in schizophrenia Advanced LB-102 into late-stage development in multiple indications with initiation ofa pivotal Phase 3 NOVA-2 trial in schizophrenia, and Phase 2 ILLUMINATE-1 trialin bipolar depression Announced pipeline expansion with plans to initiate a Phase 2 trial of LB-102 for theadjunctive treatment of major depressive disorder (MDD) in early 2027 Cash, cash equivalents, and investments of $295.2 million as of December 31, 2025, and proceeds from recent $100 million private placement, expected to provide cash runway into Q2 2029 NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc
LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NOVA-2 trial to enroll approximately 460 patients Primary endpoint to evaluate change in PANSS total score at week 6; secondary endpoints to include evaluations of negative symptoms and cognitive performance as well as safety and tolerability Topline data expected in 2H 2027 NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder (MDD), and other neuropsychiatric diseases, today announced the ini
4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
3 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
S-8 - LB PHARMACEUTICALS INC (0001691082) (Filer)
10-K - LB PHARMACEUTICALS INC (0001691082) (Filer)
8-K - LB PHARMACEUTICALS INC (0001691082) (Filer)
NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder (MDD) and other neuropsychiatric diseases, today announced the appointment of Robert Lenz, M.D., Ph.D. to its Board of Directors. "We are delighted to welcome Rob to our Board as his depth of expertise in neuroscience R&D brings significant value to LB Pharma at a time when we are advancing LB-102 into late-stage clinical development across multiple indications," said Heather Turner, Chief Executive Officer of LB Pharmaceuticals
NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointment Dr. Minako Pazdera as General Counsel. Dr. Pazdera joins LB Pharmaceuticals with more than 25 years of experience spanning corporate governance, intellectual property, strategic corporate transactions and compliance. "We are delighted to welcome Minako to LB Pharmaceuticals," said Heather Turner, Chief Executive Officer. "Dr. Pazdera has broad expertise encompassing both financial and strateg
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointments of Ellen Rose as Senior Vice President, Corporate Affairs and Lindsay Beaupre as Senior Vice President, People and Culture. "We are pleased to welcome Ellen and Lindsay to LB Pharmaceuticals," said Heather Turner, Chief Executive Officer. "Ms. Rose has extensive experience in corporate communications, investor relations, and patient advocacy within the biopharma industry. Ms. Beaupre is a sea